What 'Research Grade' Actually Requires on a COA
By Southern Labs Research Team · Published 2026-09-13
When a supplier labels a peptide "research grade," that phrase carries significant implied weight. It suggests rigorous testing, documented purity, and analytical accountability. Yet unlike pharmaceutical classifications governed by regulatory bodies, "research grade" has no universal legal definition. Any supplier can apply it freely, to any product, at any purity level, with any degree of testing documentation.
For serious research procurement, this ambiguity creates real risk. A certificate of analysis pharmaceutical manufacturers produce must meet precise, auditable standards; the COAs circulating in the peptide supply market frequently do not. The gap between a genuinely qualified reference compound and one marketed with confident but unsubstantiated language can be difficult to detect without a concrete evaluation framework.
This analysis closes that gap. It examines the purity thresholds that meaningfully distinguish research-grade tiers, the analytical methodologies that make a purity figure credible, and the specific COA fields that enable independent verification. It also addresses the New Zealand regulatory context for research compound documentation and provides a practical procurement framework for evaluating supplier claims against objective, defensible standards.
Research Grade Is a Marketing Term, Not a Regulatory Classification
No regulatory body, including Medsafe, the FDA, the EMA, or any major pharmacopoeial authority such as the USP or British Pharmacopoeia, defines "research grade" as a formal quality classification for peptide reference compounds. The term is not defined in pharmaceutical manufacturing standards frameworks, nor in equivalent frameworks operating in New Zealand. For an overview of how NZ regulatory requirements apply to research compound procurement, see what are the legal requirements for purchasing research peptides?
Without a regulatory anchor, "research grade" is self-assigned. Any supplier can apply the label regardless of how a compound was synthesised, what testing was performed, or what a certificate of analysis actually contains. Two suppliers can simultaneously claim it at purity levels differing by several percentage points, using incompatible analytical methods, and issuing COAs with entirely different fields. The designation carries no enforceable meaning.
This creates a concrete procurement problem. A purity figure without a named methodology, a COA without a traceable lot number, or a certificate issued by an unverifiable laboratory all represent documentation gaps that "research grade" labelling obscures rather than resolves. Southern Labs sets out its own documentation approach so buyers can assess it against the criteria below.
The only defensible working definition must be assembled from constituent standards: purity thresholds, methodology requirements, and COA field criteria drawn from analytical chemistry and pharmaceutical frameworks that do carry defined standards. That is what this piece constructs.
Purity Thresholds: The 95, 98, and 99 Percent Tiers and What Drives the Distinction
Purity thresholds are where a working standard begins to take shape.
Industry practice, not regulatory mandate, has produced three informal tiers: 95%+ for general research use, 98%+ for quantitative assay work, and >99% for primary reference standards and assay calibration. These reflect accumulated judgement from analytical chemists, not a codified standard. No pharmacopoeial authority has formalised them for research peptides.
The number on a COA is only as informative as the methodology behind it. A 98% HPLC-UV result and a 98% HPLC-MS result are not equivalent, the methodology section below examines why.
Equally important is what occupies the remaining 1-5%. Residual solvents, TFA counterion content, moisture in lyophilised material, and peptide-related impurities such as deletion sequences or oxidised variants each carry different implications for research validity. A single purity figure collapses these into one undifferentiated number.
The stakes are highest when the compound functions as a quantitative reference. Standard curve generation, assay validation, and comparator use all require that impurity variance be characterised, not merely bounded. Reviewing the specifications or specifications for any batch illustrates what disclosed methodology and impurity context look like in practice.
A COA reporting one purity figure without naming the method, characterising the impurity profile, or stating the calculation basis does not permit independent verification regardless of the percentage cited.
Analytical Methodology: Why the Testing Method Matters as Much as the Number
The purity tier assigned to a compound means little if the methodology behind that figure is not disclosed. Different analytical techniques answer different questions, and a COA that conflates them obscures more than it reveals.
HPLC-UV is the baseline method for peptide purity reporting, measuring UV absorbance area percentage at 214 nm or 220 nm. The limitation is structural: amino acid composition directly affects UV absorbance, co-eluting peptides of equal mass can produce unequal peak areas, which is why HPLC-UV area percentage is a screening metric rather than a mass-accurate purity determination.
HPLC-MS adds molecular weight confirmation to chromatographic separation. Deletion sequences and oxidised variants can co-elute under UV without producing a visible aberration; mass detection identifies them. Combining HPLC-UV with MS detection is therefore preferred for research-grade compounds: it separates the identity question from the purity question.
NMR provides structural confirmation independent of chromatographic separation and is particularly useful for detecting TFA or acetate counterion content, residual solvents, and structural isomers HPLC cannot resolve.
Karl Fischer titration quantifies moisture in lyophilised peptides. A compound carrying 5% moisture delivers correspondingly less active material per milligram, affecting any weight-based calculation in downstream work.
Headspace GC-MS covers residual solvents; counterion quantification addresses TFA or acetate carryover from solid-phase synthesis. Neither parameter appears in a purity figure derived from HPLC-UV alone.
Purity and identity are distinct analytical questions. A COA reporting only HPLC-UV area percentage has answered one; it has not answered the other. Reviewing the full specifications on a product listing shows what a methodology-complete documentation package looks like in practice.
Certificate of Analysis Requirements: The Fields That Enable Independent Verification
Knowing which analytical methods belong on a COA is only half the requirement. The other half is structural: the document must contain specific fields that allow a buyer to independently verify that the result relates to the material in hand, was generated by a qualified laboratory, and remains analytically current.
Batch or lot number. Each COA must carry a unique identifier traceable to a single synthesis and testing event. Generic or reused lot numbers break the chain of custody entirely; there is no way to confirm the document corresponds to the specific material received rather than an earlier or different batch.
Test date and retest date. The test date establishes when the analysis was performed. The retest or expiry date defines the analytical validity window, the period within which the reported results can be relied upon. A COA without both fields leaves the buyer unable to assess whether the data is current relative to their intended use.
Compound identity fields. Molecular formula, molecular weight, CAS number, and amino acid sequence (for peptides) must all be present. These fields allow cross-referencing against pharmacopoeial monographs or published reference data and are the minimum required for unambiguous compound identification before use.
Analytical method citations. Every reported parameter must name the specific method used: for example, RP-HPLC-UV at 220 nm with column specification and mobile phase, or ESI-MS with ionisation parameters. Without this information, the result cannot be audited or reproduced by the receiving laboratory.
Purity result with method basis. The purity figure must state whether it represents area percentage, mass percentage, or a value corrected for moisture and counterion content. Each basis yields a different number from the same raw data; an undeclared basis makes comparison between suppliers meaningless.
Identity confirmation as a separate field. Identity confirmation by MS or NMR must appear as a distinct result, not as a footnote to the purity figure. Purity and identity are separate analytical determinations requiring separate reporting.
Moisture content. Reported as a percentage by Karl Fischer titration or an equivalent gravimetric method, as a standalone field.
Residual solvent and counterion data. TFA or acetate counterion content from synthesis, and residual process solvents such as acetonitrile or DMF, must be reported separately. These are not captured by HPLC-UV purity and materially affect the usable content per milligram.
Issuing laboratory. The name of the testing facility, and its accreditation status where available, should appear on the document, so a buyer can see who produced the result. Southern Labs publishes the manufacturer's batch COA for each lot in its COA library, identified by lot number.
In-House Testing vs. Third-Party Verification: How to Evaluate Lab Independence
Field completeness establishes what a COA reports; laboratory independence determines whether that report can be trusted.
A COA issued by a manufacturer's own laboratory is, in effect, self-certification, and that is the industry norm for research compounds. Its accuracy depends on that manufacturer's internal quality systems, which an external buyer cannot directly audit. This is not a reason to dismiss such a document — it is a reason to know which kind you are holding.
A third-party COA is issued by a laboratory whose only relationship to the supplier is a testing contract. That laboratory has no stake in the result. This absence of financial interest is the structural basis of analytical independence, not a courtesy claim.
The internationally recognised marker of laboratory competence is ISO/IEC 17025 accreditation. Accreditation by a national body such as IANZ in New Zealand confirms the laboratory operates validated methods, calibrated instruments, and documented quality systems subject to periodic external audit. An internal supplier laboratory may hold a quality management certification that covers process compliance but does not independently verify analytical method competence, a distinction ISO/IEC 17025 accreditation is specifically designed to address.
When reviewing any COA, the issuing laboratory name should be verifiable through a public accreditation register. A laboratory that cannot be located through IANZ or an equivalent national body warrants direct scrutiny before relying on its results.
One further check: ask whether the supplier can provide the original document as issued by the testing laboratory. Reformatted or transcribed versions introduce transcription error risk and remove the laboratory's direct accountability for the data. Southern Labs supplies the manufacturer's original batch COA, so buyers can see exactly who produced the data and weigh it themselves.
The New Zealand Regulatory Context for Research Compound Documentation
Even a fully documented third-party COA operates within a market that has no domestic regulatory definition of what it is supposed to prove, a gap the New Zealand context makes concrete.
New Zealand's Medicines Act 1981 governs medicines supply through Medsafe, but its scope is limited to products intended for therapeutic or diagnostic use in humans or animals. Research compounds supplied solely for laboratory purposes, with no intended human or animal use, operate outside that framework. The consequence cuts both ways: such compounds are not subject to medicines regulation, but there is also no corresponding domestic quality standard that research suppliers are legally required to meet.
This absence means "research grade" carries no enforceable meaning in the NZ market. No domestic regulator defines it, audits it, or penalises its misuse.
In practice, NZ researchers draw on international frameworks to construct a working standard. ICH Q2(R1) provides validated analytical methodology guidance adopted by regulatory agencies globally. PIC/S guides inform pharmaceutical quality systems. Where peptide-specific monographs exist, the USP, Ph. Eur., and BP supply characterisation and purity specifications against which a COA result can be cross-referenced.
ISO 17034, which governs reference material producers and specifies documentation, characterisation, and stability requirements, provides the clearest benchmark for what properly characterised reference material documentation should contain, though it is not universally adopted by peptide suppliers.
For researchers in institutional or grant-funded settings, this gap has direct procurement implications. Without a regulatory floor, supplier selection requires a documented rationale. A rigorous COA requirement is not bureaucratic caution; it is the only objective basis available for justifying that selection, and for demonstrating due diligence when no regulator has done it on your behalf.
A Practical COA Evaluation Framework for Research Procurement
Given that buyer-constructed criteria are the only enforceable standard in this market, the following checklist provides an objective basis for evaluating any COA against defensible research-grade requirements.
Identity fields. The COA must include molecular formula, molecular weight, CAS number, and peptide sequence. Each should be independently cross-referenceable against published reference data. Absence of any field removes the ability to verify compound identity before use.
Purity with named method. A purity figure is only interpretable if the generating method is stated. HPLC-UV is the minimum acceptable basis; HPLC-MS or NMR is required for identity confirmation. Method parameters, specifically detection wavelength, column specification, and solvent system, must be cited so the result can be reproduced or audited.
Separate analyte reporting. Moisture content, counterion content (TFA or acetate), and residual solvents must appear as distinct fields. Standard HPLC-UV purity does not capture these, and each materially reduces usable active content per unit mass. A COA reporting only a single purity figure is analytically incomplete.
Batch-specific traceability. A unique lot number and current test date are required; the COA fields section above explains the traceability chain each establishes. Reviewing product specifications that carry lot-referenced third-party data illustrates what this looks like in practice.
A named issuing laboratory. The testing facility should be named so a buyer can see who produced the result and, where the laboratory holds ISO/IEC 17025 accreditation or equivalent, confirm it. Where the certificate comes from the manufacturer's own laboratory, that should be stated plainly rather than implied otherwise.
Applied as a procurement checklist, this framework allows direct comparison between supplier documentation packages without relying on how a supplier has chosen to label their product tier.
Conclusion
Applied to any supplier's documentation, the checklist in the preceding section resolves what the label never will. As established above, "research grade" carries no regulatory weight in the New Zealand market. The standard is buyer-constructed or it does not exist.
The checklist above defines the minimum viable COA; a document missing any of those fields cannot support independent verification, regardless of what purity figure it reports or how the product is labelled.
A supplier who will not tell you what its documentation is, or who produced it, has not given you enough to judge. The label is not evidence; the documentation is.
Southern Labs publishes the manufacturer's batch COA by lot number for every product it supplies, so researchers can see the source of the data and apply the checklist above themselves. For NZ researchers who need domestic stock and fast local dispatch, that is available without the delays and uncertainties of international sourcing.